FDA Approves Kite Pharma’s Cancer Drug Yescarta

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

FDA Approves Kite Pharma’s Cancer Drug Yescarta
Photo by Drew Hays on Unsplash

Santa Monica-based Kite Pharma, a subsidiary of biopharma giant Gilead Sciences, announced on Friday that it has received approval from the Food and Drug Administration for a new immunotherapy drug that can be used in the early-stage treatment of certain cancers.


Yescarta, an intravenous CAR-T cell treatment that aims to bolster the immune system to fight cancer cells, is the first therapeutic of its kind to receive FDA approval for the early treatment of large B-cell lymphoma—a type of non-Hodgkin lymphoma—that has either relapsed or can’t be addressed with other cancer treatments like chemoimmunotherapy.

Most CAR-T cell therapies are reserved as a last resort for cancer patients who have exhausted all other options. At that point, however, their immune systems may be too weak to effectively utilize the therapeutic. While most clinical CAR-T cell trials involve patients who are at an advanced stage in their cancer treatments, Yescarta’s clinical trial was filled with patients who used the drug as a second- or third-resort.

CAR-T cell therapies have taken the oncology world by storm as a promising, potentially less invasive route for treating cancers, with many local biotech firms making moves in the space. In January, West Hills-based ImmPACT Bio raised $111 million to further its work of reengineering patients’ cells to boost the immune system. Culver City-based Appia Bio, meanwhile, emerged from stealth last spring to create off-the-shelf cell therapies that can be delivered quicker and cheaper to patients, and inked a deal with Kite Pharma last August to develop CAR-T cell treatments.

Kite Pharma has focused almost exclusively on CAR-T cell therapies since it was founded in 2009. Gilead Sciences acquired Kite for $11.9 billion in 2017.

“Kite started with a very bold goal: creating the hope of survival through cell therapy,” Kite CEO Christi Shaw said in a statement. “Today’s FDA approval brings that hope to more patients by enabling the power of CAR-T cell therapy to be used earlier in the treatment journey. This milestone has been years in the making.”

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

LA-Based Apex Is Tapping Into the Small Satellite Market by Making Buses for Spacecraft

Spencer Rascoff

Spencer Rascoff serves as executive chairman of dot.LA. He is an entrepreneur and company leader who co-founded Zillow, Hotwire, dot.LA, Pacaso and Supernova, and who served as Zillow's CEO for a decade. During Spencer's time as CEO, Zillow won dozens of "best places to work" awards as it grew to over 4,500 employees, $3 billion in revenue, and $10 billion in market capitalization. Prior to Zillow, Spencer co-founded and was VP Corporate Development of Hotwire, which was sold to Expedia for $685 million in 2003. Through his startup studio and venture capital firm, 75 & Sunny, Spencer is an active angel investor in over 100 companies and is incubating several more.

​Ian Cinnamon
Ian Cinnamon

On this episode of Office Hours, Apex founder and CEO Ian Cinnamon discusses the importance of investing in space exploration and shares his thoughts on the evolving space ecosystem in Los Angeles.


Read moreShow less
https://twitter.com/spencerrascoff
https://www.linkedin.com/in/spencerrascoff/
admin@dot.la

This Week in ‘Raises’: Measurabl Snags $93M, Selva Ventures Grabs $34M

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

Raises
Image by Joshua Letona

A local data management platform company lands fresh funding to help commercial real estate owners reduce carbon footprint, while one Los Angeles-based venture firm closes its second fund to accelerate the growth of emerging companies across health, wellness, beauty and personal care.

***

Read moreShow less

McKinsey & Company Launches InLA Accelerator To Help Underrepresented Founders Tackle Startup Challenges

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

McKinsey & Company Launches InLA Accelerator To Help Underrepresented Founders Tackle Startup Challenges
InLA

In 2022, female founders saw a 28% decline in overall U.S. funding, while Black-led startups saw a 38% decline in total capital received. In an effort to increase funding for minority-led startups, global venture firm McKinsey & Company is launching InLA, an accelerator program for underrepresented founders.

“This effort is something that the firm has been really excited about for a long time,” Engagement Manager Elkhyn Rivas Rodriguez said. “There's obviously a meaningful and growing startup community out here and just from a diversity standpoint, LA is incredibly diverse and multi-ethnic and multicultural. So we think that there will be a really great pool of potential companies to partner with.”

Read moreShow less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending